05 April 2016
In a recent study of contract research organizations (CROs) around the world, the Pharma’s Almanac recognized Smithers Avanza among the top bioanalytical CROs. Pharma’s Almanac is published quarterly by independent researcher Nice Insight.
Smithers Avanza ranked high in terms of quality, reliability, productivity, affordability, innovation and regulatory history. The report noted:
Nice Insight’s Top Companies lists are comprised of the highest scoring companies, as rated by buyers of outsourced services.
“We are thrilled to be recognized by Pharma’s Almanac in this way, as it demonstrates that our clients see the benefits of working with our expert large molecule bioanalytical team,” said Michael Hochschwender, President, Smithers Avanza. “This is a great affirmation that our commitment to quality and service, as well as our scientific expertise, are being noticed and appreciated by our clients.”
The Pharma’s Almanac is a special supplement published quarterly by Nice Insight. It contains results from independent annual industry surveys that evaluated 74 CROs from all over the world, focusing on buyer needs, supplier evaluation and selection criteria, and ratings for CROs and contract development and manufacturing organizations (CDMOs). The organizations evaluated ranged from privately held CROs such as Smithers Avanza, to large, publicly-traded companies with broad service offerings such as Quest Diagnostics Clinical Trials, Parexel and ICON.